Kenvue Inc. $KVUE Shares Sold by Bahl & Gaynor Inc.

Key Points

• Bahl & Gaynor Inc. reduced its stake in Kenvue Inc. by 6.8%, now holding 179,729 shares worth $4.31 million after selling 13,077 shares.
• Kenvue announced a quarterly dividend increase to $0.2075, providing a yield of 3.8%, with a payout ratio of 112.16%.
• The company reported $0.29 earnings per share for the last quarter, exceeding analyst expectations, despite a 4% decline in revenue year-over-year.

Bahl & Gaynor Inc. cut its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 179,729 shares of the company's stock after selling 13,077 shares during the quarter. Bahl & Gaynor Inc.'s holdings in Kenvue were worth $4,310,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its holdings in Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after acquiring an additional 4,034 shares in the last quarter. IFP Advisors Inc grew its position in shares of Kenvue by 25.3% in the first quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock valued at $369,000 after purchasing an additional 3,081 shares during the period. Starboard Value LP purchased a new stake in shares of Kenvue during the fourth quarter worth about $467,864,000. Kingswood Wealth Advisors LLC purchased a new stake in shares of Kenvue during the first quarter worth about $413,000. Finally, Cooper Investors PTY Ltd. raised its position in shares of Kenvue by 39.7% during the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock worth $20,577,000 after purchasing an additional 244,043 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Down 1.9%

Shares of KVUE traded down $0.40 during mid-day trading on Tuesday, reaching $20.80. The stock had a trading volume of 18,005,724 shares, compared to its average volume of 18,522,460. Kenvue Inc. has a 52-week low of $19.75 and a 52-week high of $25.17. The firm has a market cap of $39.91 billion, a price-to-earnings ratio of 28.10, a P/E/G ratio of 3.04 and a beta of 0.83. The business's fifty day moving average is $21.50 and its 200 day moving average is $22.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the previous year, the business posted $0.32 EPS. Kenvue's revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 4.0%. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Bank of America lowered their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Barclays decreased their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Zacks Research upgraded Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Citigroup decreased their price objective on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.